Tumor Vaccine and Interferon Gamma in Treating Patients With Refractory Epithelial Ovarian Cancer

Completed · Phase 1

Conditions studied: Recurrent Ovarian Epithelial Cancer

In brief

Phase I trial to study the effectiveness of a tumor cell vaccine and interferon gamma in patients with refractory epithelial ovarian cancer. Vaccines made from a person's cancer cells may make the body build an immune response to and kill their tumor cells. Combining vaccine therapy with interferon gamma may be a more effective treatment for epithelial ovarian cancer

Key facts

Study ID

NCT00004032

Run by

National Cancer Institute (NCI)

People needed

12

Starts

1997-10-01

Last updated by the study team

2013-01-23

Who can join

Age: any. Sex: female. Healthy volunteers: not accepted.

You may qualify if…

• Diagnosis of ovarian epithelial carcinoma
• Previously treated with an adequate course of platinum based chemotherapy
• Evidence of intraabdominal disease
• No significant adhesions
• Performance status - Zubrod 0-2
• Lymphocyte count at least 500/mm\^3
• Bilirubin no greater than 1.5 mg/dL
• SGOT less than 2.5 times upper limit of normal
• Creatinine no greater than 1.5 mg/dL
• No major disorder of the cardiovascular system
• No major disorder of the pulmonary system
• Not pregnant or nursing
• Fertile patients must use effective contraception
• Successful placement of peritoneal catheter
• No overt autoimmune disease
• No concurrent chronic steroid therapy
• No prior radiotherapy
• Prior surgery allowed
• Recovered from prior therapy

Where it is running

• M D Anderson Cancer Center — Houston, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.